Your browser doesn't support javascript.
loading
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Drummond, Catherine J; Esfandiari, Arman; Liu, Junfeng; Lu, Xiaohong; Hutton, Claire; Jackson, Jennifer; Bennaceur, Karim; Xu, Qing; Makimanejavali, Aditya Rao; Del Bello, Fabio; Piergentili, Alessandro; Newell, David R; Hardcastle, Ian R; Griffin, Roger J; Lunec, John.
Afiliación
  • Drummond CJ; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Esfandiari A; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Liu J; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Lu X; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Hutton C; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Jackson J; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Bennaceur K; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Xu Q; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Makimanejavali AR; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Del Bello F; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
  • Piergentili A; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
  • Newell DR; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Hardcastle IR; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Griffin RJ; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
  • Lunec J; Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
Oncotarget ; 7(29): 46203-46218, 2016 Jul 19.
Article en En | MEDLINE | ID: mdl-27323823
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-mdm2 Tipo de estudio: Diagnostic_studies Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-mdm2 Tipo de estudio: Diagnostic_studies Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido